These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 30577194)

  • 1. Effect of Systematic Conversion to Generic Mycophenolate Mofetil (MMF) in Kidney Transplantation: A Single-Center Clinical Experience from Japan.
    Hirano H; Matsunaga T; Maenosono R; Taniguchi S; Uehara H; Nomi H; Kano Y; Fujiwara Y; Ichihashi A; Kobayashi D; Tsutsumi T; Komura K; Ibuki N; Inamoto T; Matsumura H; Ashida A; Azuma H
    Transplant Proc; 2018 Dec; 50(10):3255-3257. PubMed ID: 30577194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of generics in kidney transplant: mycophenolate mofetil 500 versus mycophenolate: 2-year results.
    Abdallah TB; Ounissi M; Cherif M; Helal I; Karoui C; Mhibik S; Bacha MM; Abderrahim E; Kheder A
    Exp Clin Transplant; 2010 Dec; 8(4):292-6. PubMed ID: 21143094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunosuppressive regimens containing generic mycophenolate mofetil (Myfenax) in de novo renal transplant recipients--preliminary results of 6-month observation.
    Rutkowski B; Bzoma B; Dębska-Ślizień A; Chamienia A
    Ann Transplant; 2011; 16(4):74-80. PubMed ID: 22210425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.
    Vanhove T; Kuypers D; Claes KJ; Evenepoel P; Meijers B; Naesens M; Vanrenterghem Y; Cornelis T; Bammens B
    Transpl Int; 2013 Aug; 26(8):813-21. PubMed ID: 23746202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group.
    Lancet; 1995 May; 345(8961):1321-5. PubMed ID: 7752752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
    Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A
    Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Descriptive retrospective comparative study between two brands of mycophenolate mofetil used in Uruguay: innovator versus generic (Suprimun).
    Gonzalez-Martínez F; Orihuela S; Orihuela N; Manzo L; Nuñez N; Nin M
    Transplant Proc; 2014 Nov; 46(9):2996-9. PubMed ID: 25420809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic formulation of mycophenolate mofetil (Myfenax) in de novo renal transplant recipients: results of 12-month observation.
    Rutkowski B; Bzoma B; Dębska-Ślizień A; Chamienia A
    Transplant Proc; 2014 Oct; 46(8):2683-8. PubMed ID: 25380894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance immunosuppression with mycophenolate mofetil and corticosteroids in pediatric kidney transplantation: temporary benefit but not without risk.
    Cransberg K; Cornelissen M; Lilien M; Van Hoeck K; Davin JC; Nauta J
    Transplantation; 2007 Apr; 83(8):1041-7. PubMed ID: 17452893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels.
    Dubrey SW; Holt DW; Banner N
    Ther Drug Monit; 1999 Jun; 21(3):325-6. PubMed ID: 10365646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group.
    Am J Kidney Dis; 1999 Aug; 34(2):296-303. PubMed ID: 10430977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
    Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil absorption quotient: interest to clinical practice.
    Fernández A; Villafruela J; Amezquita Y; Caldés S; Marcen R; Galeano C; Pascual J; Rodriguez-Mendiola N; Ortuño J
    Transplant Proc; 2009; 41(6):2317-9. PubMed ID: 19715906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improved immunosuppression leads to better kidney transplantations].
    Ekberg H
    Lakartidningen; 2012 Sep 26-Oct 9; 109(39-40):1739-42. PubMed ID: 23097879
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid.
    Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I
    Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
    Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.